Abstract
The study aimed to investigate the role of oxidised low-density lipoprotein (oxLDL)/lectin-like-oxLDL receptor-1 (LOX-1) in coronary artery lesions (CALs) in Kawasaki disease (KD) and of plasma oxLDL concentration in the early prediction of CALs in KD. This prospective study included 80 KD patients, 20 febrile and 20 healthy children. oxLDL, LOX-1 and other parameters were analysed in the acute phase. Plasma oxLDL concentration and LOX-1 mRNA expression in peripheral blood mononuclear cells (PBMCs) were significantly increased in KD patients compared with febrile and healthy children (P < 0.001 and P = 0.022, respectively), particularly in the group with CALs (P < 0.001 and P = 0.027, respectively). Coronary Z-score was significantly correlated with plasma oxLDL concentration and LOX-1 mRNA expression (r = 0.739 and 0.637, respectively; P < 0.01). The sensitivity and specificity of predicting CALs were 71.4% and 77.2%, respectively, at plasma oxLDL concentration ≥ 12.38 mU/L. oxLDL/LOX-1 may be involved in CAL development. The plasma oxLDL concentration in the acute phase is a potentially useful biological indicator for predicting CAL in KD patients.
Similar content being viewed by others
Abbreviations
- ALB:
-
albumin
- ALT:
-
alanine aminotransferase
- AST:
-
aspartate aminotransferase
- CAL:
-
coronary artery lesion
- CRP:
-
C-reactive protein
- ELISA:
-
enzyme-linked immunosorbent assay
- ESR:
-
erythrocyte sedimentation rate
- Hb:
-
haemoglobin
- IVIG:
-
intravenous immunoglobulin
- LOX-1:
-
lectin-like-oxLDL receptor-1
- Na+ :
-
serum sodium
- NT-proBNP:
-
N-terminal pro brain natriuretic peptide
- oxLDL:
-
oxidised low-density lipoprotein
- N:
-
neutrophil ratio
- Plt:
-
platelet count
- KD:
-
Kawasaki disease
- NCAL:
-
non-CAL
- PCR:
-
polymerase chain reaction
- WBC:
-
white blood cell count
- PBMCs:
-
peripheral blood mononuclear cells
- TG:
-
triglyceride
- TC:
-
total cholesterol
- LDL:
-
low-density lipoprotein cholesterol
- HDL:
-
high-density lipoprotein cholesterol
References
McCrindle, B. W., Rowley, A. H., Newburger, J. W., et al. (2017). Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for hearth professionals from the American Heart Association. Circulation, 135(17), e927–e999.
Cheung, Y. F. (2014). Vascular health late after Kawasaki disease: Implications for accelerated atherosclerosis. Korean Journal of Pediatrics, 57, 472–478.
Zhang, J., Tuokan, T., & Shi, Y. (2018). Sudden death as a sequel of ruptured giant coronary artery aneurysm in Kawasaki disease. The American Journal of Forensic Medicine and Pathology, 39(4), 375–377.
Nomura, O., Fukuda, S., Ota, E., Ono, H., Ishiguro, A., & Kobayashi, T. (2016). Monoclonal antibody therapy for Kawasaki disease: A protocol for systematic reviews and meta-analysis. Systematic Reviews, 5(60). https://doi.org/10.1186/s13643-016-0236-2.
Youn, Y., Kim, J., Hong, Y. M., & Sohn, S. (2016). Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. The Pediatric Infectious Disease Journal, 35(4), 457–459. https://doi.org/10.1097/INF.0000000000001039.
Singh, S., Bhattad, S., & Gupta, A. (2016). Mortality in children with Kawasaki disease: 20 years of experience from a tertiary care Centre in North India. Clinical and Experimental Rheumatology, 34(3 Suppl 97), 129–133.
Woo, H. O. (2019). Predictive risk factors of coronary artery aneurysms in Kawasaki disease. Korean Journal of Pediatrics. https://doi.org/10.3345/kjp.2019.00073.
Sun, Y., Yuan, Y., Yan, H., et al. (2015). Plasma H2S predicts coronary artery lesions in children with Kawasaki disease. Pediatrics International, 57, 840–844.
Jeon, S. K., Kim, G., Ko, H., Byun, J. H., & Lee, H. D. (2018). Risk factors for the occurrence and persistence of coronary aneurysm in Kawasaki disease. Korean Journal of Pediatrics. https://doi.org/10.3345/kjp.2018.07052.
Yahata, T., & Hamaoka, K. (2017). Oxidative stress and Kawasaki disease: How is oxidative stress involved from the acute stage to the chronic stage? Rheumatology (Oxford), 56, 6–13.
Koibuchi, H., Kotani, K., Minami, T., Konno, K., & Taniguchi, N. (2016). Endothelial dysfunction by flow-mediated dilation assessed ultrasonically in patients with Kawasaki disease. Minerva Pediatrica, 68, 143–147.
Mori, Y., Katayama, H., Kishi, K., Ozaki, N., Shimizu, T., & Tamai, H. (2016). Persistent high fever for more than 10 days during acute phase is a risk factor for endothelial dysfunction in children with a history of Kawasaki disease. Journal of Cardiology, 68, 71–75.
Lubrano, V., & Balzan, S. (2016). Roles of LOX-1 in microvascular dysfunction. Microvascular Research, 105, 132–140. https://doi.org/10.1016/j.mvr.2016.02.006.
Tsai, K. L., Chang, Y. L., Huang, P. H., Cheng, Y. H., Liu, D. H., Chen, H. Y., & Kao, C. L. (2016). Ginkgo biloba extract inhibits oxidised low-density lipoprotein (oxLDL)-induced matrix metalloproteinase activation by the modulation of the lectin-like oxLDL receptor 1-regulated signalling pathway in human umbilical vein endothelial cells. Journal of Vascular Surgery, 63, 204–215.e1.
Ji, K. T., Qian, L., Nan, J. L., et al. (2015). Ox-LDL induces dysfunction of endothelial progenitor cells via activation of NF-κB. BioMed Research International, 2015, 175291.
Stancel, N., Chen, C. C., Ke, L. Y., Chu, C. S., Lu, J., Sawamura, T., & Chen, C. H. (2016). Interplay between CRP, atherogenic LDL, and LOX-1 and its potential role in the pathogenesis of atherosclerosis. Clinical Chemistry, 62(2), 320–327. https://doi.org/10.1373/clinchem.2015.243923.
Arjuman, A., & Chandra, N. C. (2017). LOX-1: A potential target for therapy in atherosclerosis; an in vitro study. The International Journal of Biochemistry & Cell Biology, 91, 65–80. https://doi.org/10.1016/j.biocel.2017.08.013.
Di Pietro, N., Formoso, G., & Pandolfi, A. (2016). Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascular Pharmacology, 84, 1–7. https://doi.org/10.1016/j.vph.2016.05.013.
Freeman, A. F., & Shulman, S. T. (2006). Kawasaki disease: Summary of the American Heart Association guidelines. American Family Physician, 74(7), 1141–1148.
Saguil, A., Fargo, M., & Grogan, S. (2015). Diagnosis and management of Kawasaki disease. American Family Physician, 91(6), 365–371.
Newburger, J. W., Takahashi, M., & Burns, J. C. (2016). Kawasaki disease. Journal of the American College of Cardiology, 67, 1738–1749.
Vostokova, A. A., Grunina, E. A., & Klemenov, A. V. (2016). Aftermaths of lesions of coronary arteries in Kawasaki disease. Angiol Sosud Khir, 22(1), 46–51.
Singhal, M., Vignesh, P., Khandelwal, N., & Singh, S. (2018). Calcified saccular coronary artery aneurysm of Kawasaki disease. Journal of Clinical Rheumatology. https://doi.org/10.1097/RHU.0000000000000953.
Tsuda, E., Tsujii, N., & Hayama, Y. (2018). Stenotic lesions and the maximum diameter of coronary artery aneurysms in Kawasaki disease. The Journal of Pediatrics, 194, 165–170.e2. https://doi.org/10.1016/j.jpeds.2017.09.077.
Gravel, H., Curnier, D., Dallaire, F., Fournier, A., Portman, M., & Dahdah, N. (2015). Cardiovascular response to exercise testing in children and adolescents late after Kawasaki disease according to coronary condition upon onset. Pediatric Cardiology, 36(7), 1458–1464. https://doi.org/10.1007/s00246-015-1186-5.
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016). LOX-1-mediated effects on vascular cells in atherosclerosis. Cellular Physiology and Biochemistry, 38(5), 1851–1859. https://doi.org/10.1159/000443123.
Lubrano, V., & Balzan, S. (2014). LOX-1 and ROS, inseparable factors in the process of endothelial damage. Free Radical Research, 48(8), 841–848. https://doi.org/10.3109/10715762.2014.929122.
Zhao, W., Ma, G., & Chen, X. (2014). Lipopolysaccharide induced LOX-1 expression via TLR4/MyD88/ROS activated p38MAPK/NF-κB pathway. Vascular Pharmacology, 63(3), 162–172.
Ishikawa, T., & Seki, K. (2018). The association between oxidative stress and endothelial dysfunction in early childhood patients with Kawasaki disease. BMC Cardiovascular Disorders, 18(1), 30. https://doi.org/10.1186/s12872-018-0765-9.
Takahashi, K., Oharaseki, T., & Yokouchi, Y. (2018). Histopathological aspects of cardiovascular lesions in Kawasaki disease. International Journal of Rheumatic Diseases, 21(1), 31–35. https://doi.org/10.1111/1756-185X.13207.
Chen, K. Y., Curtis, N., Dahdah, N., Kowalski, R., Cheung, M., & Burgner, D. P. (2016). Kawasaki disease and cardiovascular risk: A comprehensive review of subclinical vascular changes in the longer term. Acta Paediatrica, 105, 752–761.
Duan, C., Du, Z. D., Wang, Y., & Jia, L. Q. (2014). Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease. World Journal of Pediatrics, 10, 232–237.
Huang, M., Dong, G. Q., Jiang, H. Y., Zhang, J. Y., & Shi, X. J. (2015). Serum adiponectin levels in children with Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi, 17(1), 35–39.
Zhang, H., Xu, M. G., Xie, L. J., Huang, M., Shen, J., & Xiao, T. T. (2016). Meta-analysis of risk factors associated with atherosclerosis in patients with Kawasaki disease. World Journal of Pediatrics, 12(3), 308–313.
Mostafavi, N., Haghjooy-Javanmard, S., Presidend, N., Manssori, N. S., & Kelishadi, R. (2015). Persistence of endothelial cell damage late after Kawasaki disease in patients without coronary artery complications. Advanced Biomedical Research, 4, 25. https://doi.org/10.4103/2277-9175.150393.
Pinto, F. F., Gomes, I., Loureiro, P., Laranjo, S., Timóteo, A. T., & Carmo, M. M. (2017). Vascular function long term after Kawasaki disease: Another piece of the puzzle? Cardiology in the Young, 27(3), 488–497. https://doi.org/10.1017/S1047951116000780.
McCrindle, B. W., & Harris, K. C. (2018). Coronary artery aneurysms after Kawasaki disease: Understanding the pathology. The Canadian Journal of Cardiology, 34(9), 1094–1097.
Denby, K. J., Clark, D. E., & Markham, L. W. (2017). Management of Kawasaki disease in adults. Heart, 103(22), 1760–1769. https://doi.org/10.1136/heartjnl-2017-311774.
Kim, M. K., Song, M. S., & Kim, G. B. (2018). Factors predicting resistance to intravenous immunoglobulin treatment and coronary artery lesion in patients with Kawasaki disease: Analysis of the Korean nationwide multicenter survey from 2012 to 2014. Korean Circulation Journal, 48(1), 71–79.
Lee, H. Y., & Song, M. S. (2016). Predictive factors of resistance to intravenous immunoglobulin and coronary aneurysm lesions in Kawasaki disease. Korean Journal of Pediatrics, 59(12), 477–482.
Dionne, A., & Dahdah, N. (2018). A decade of NT-proBNP in acute Kawasaki disease, from physiological response to clinical relevance. Children, 5(10), 141.
What Are the Clinical Implications
Elevated plasma oxLDL concentration in the acute phase can predict CAL in KD.
A study on oxLDL/LOX-1 and its related signalling pathways may provide a new breakthrough for the prevention and treatment of CAL caused by KD.
Funding
This work was supported by grants from the Natural Science Foundation of Zhejiang Province (No. LQ16H020008, LQ15H020006), Medical and Health Project of Zhejiang Province (No. 2017KY465, 2014KYA41) and Science and Technology Project of Wenzhou (No. Y20170134), Zhejiang, China.
Author information
Authors and Affiliations
Contributions
Study conception and design: Yue-E He, Mao-Ping Chu; data acquisition: Yue-E He, Mao-Ping Chu, Hui-Xian Qiu, Rong-Zhou Wu; analysis and data interpretation: Xing Rong, Hai-Tang Xu, Ru-Lian Xiang; drafting of the manuscript; critical revision: Yue-E He, Mao-Ping Chu.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
The study was conducted according to the Declaration of Helsinki. The ethical committee of the Wenzhou Medical University approved the study. No animal studies were carried out by the authors for this article.
Informed Consent
The parents of all participants provided written informed consent.
Additional information
Associate Editor Craig Stolen oversaw the review of this article
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
He, YE., Qiu, HX., Wu, RZ. et al. Oxidised Low-Density Lipoprotein and Its Receptor-Mediated Endothelial Dysfunction Are Associated with Coronary Artery Lesions in Kawasaki Disease. J. of Cardiovasc. Trans. Res. 13, 204–214 (2020). https://doi.org/10.1007/s12265-019-09908-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-019-09908-y